Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib, Camrelizumab, and Capecitabine in High Relapse Risk TNBC
NCT06992336Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2031
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, camrelizumab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2025; status: recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06992336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06992336.